DualityBio tries to float again
The group expects to raise nearly $170m.
Merck takes on the TROP2 leaders again in breast cancer
The company is starting a phase 3 trial of sacituzumab tirumotecan in first-line TNBC.
Merck gets saci in ovarian
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
FDA red and green lights: January 2025
AstraZeneca bags three of the month’s four oncology approvals.
The month ahead: January’s upcoming events
Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.
Biohaven aims to become an oncology fast follower
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
